PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
USA - NASDAQ:PCRX - US6951271005 - Common Stock
26.51 USD
-0.14 (-0.53%)
Overall PCRX gets a fundamental rating of 5 out of 10. We evaluated PCRX against 196 industry peers in the Pharmaceuticals industry. PCRX has an average financial health and profitability rating. PCRX is cheap, but on the other hand it scores bad on growth. With these ratings, PCRX could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
PCRX had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -8.29%, PCRX is doing good in the industry, outperforming 68.88% of the companies in the same industry.
PCRX has a better Return On Equity (-16.82%) than 70.92% of its industry peers.
PCRX has a Return On Invested Capital of 3.88%. This is amongst the best in the industry. PCRX outperforms 81.12% of its industry peers.
PCRX had an Average Return On Invested Capital over the past 3 years of 4.17%. This is significantly below the industry average of 15.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROIC | 3.88% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
1.3 Margins
The Operating Margin of PCRX (9.90%) is better than 82.65% of its industry peers.
In the last couple of years the Operating Margin of PCRX has grown nicely.
PCRX has a Gross Margin of 78.19%. This is amongst the best in the industry. PCRX outperforms 84.69% of its industry peers.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% |
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
Compared to 1 year ago, PCRX has less shares outstanding
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
The debt/assets ratio for PCRX is higher compared to a year ago.
2.2 Solvency
PCRX has an Altman-Z score of 1.68. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
PCRX's Altman-Z score of 1.68 is fine compared to the rest of the industry. PCRX outperforms 62.76% of its industry peers.
PCRX has a debt to FCF ratio of 4.96. This is a neutral value as PCRX would need 4.96 years to pay back of all of its debts.
PCRX has a Debt to FCF ratio of 4.96. This is amongst the best in the industry. PCRX outperforms 83.67% of its industry peers.
PCRX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
PCRX has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Altman-Z | 1.68 |
ROIC/WACC0.45
WACC8.54%
2.3 Liquidity
PCRX has a Current Ratio of 2.38. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX has a Current ratio (2.38) which is comparable to the rest of the industry.
PCRX has a Quick Ratio of 1.91. This is a normal value and indicates that PCRX is financially healthy and should not expect problems in meeting its short term obligations.
PCRX has a Quick ratio (1.91) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.92%.
The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -17.68% in the last year.
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
3.2 Future
The Earnings Per Share is expected to grow by 5.92% on average over the next years.
PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.56% yearly.
EPS Next Y-9.95%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.66, which indicates a very decent valuation of PCRX.
91.84% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.41.
With a Price/Forward Earnings ratio of 7.97, the valuation of PCRX can be described as very cheap.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 90.31% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (22.88), we can say PCRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.66 | ||
| Fwd PE | 7.97 |
4.2 Price Multiples
PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 92.86% of the companies in the same industry.
PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 91.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.17 | ||
| EV/EBITDA | 7.42 |
4.3 Compensation for Growth
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.62
EPS Next 2Y1.81%
EPS Next 3Y6.01%
5. Dividend
5.1 Amount
No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PCRX (9/19/2025, 10:13:03 AM)
26.51
-0.14 (-0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners111.46%
Inst Owner Change0.2%
Ins Owners0.8%
Ins Owner Change0.59%
Market Cap1.19B
Analysts76.92
Price Target38.15 (43.91%)
Short Float %14.98%
Short Ratio9.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.06%
Min EPS beat(2)1.99%
Max EPS beat(2)2.13%
EPS beat(4)4
Avg EPS beat(4)5.22%
Min EPS beat(4)1.99%
Max EPS beat(4)9.93%
EPS beat(8)5
Avg EPS beat(8)3.99%
EPS beat(12)6
Avg EPS beat(12)-0.53%
EPS beat(16)8
Avg EPS beat(16)-3.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.46%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-2.98%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.49%
Revenue beat(12)1
Avg Revenue beat(12)-2.62%
Revenue beat(16)1
Avg Revenue beat(16)-2.55%
PT rev (1m)-4.1%
PT rev (3m)-3.11%
EPS NQ rev (1m)-0.91%
EPS NQ rev (3m)3.27%
EPS NY rev (1m)-2.34%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)-0.72%
Revenue NQ rev (3m)-0.19%
Revenue NY rev (1m)-0.5%
Revenue NY rev (3m)-0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.66 | ||
| Fwd PE | 7.97 | ||
| P/S | 1.69 | ||
| P/FCF | 10.17 | ||
| P/OCF | 8.85 | ||
| P/B | 1.57 | ||
| P/tB | 3.78 | ||
| EV/EBITDA | 7.42 |
EPS(TTM)3.06
EY11.54%
EPS(NY)3.33
Fwd EY12.55%
FCF(TTM)2.61
FCFY9.83%
OCF(TTM)2.99
OCFY11.29%
SpS15.71
BVpS16.87
TBVpS7.01
PEG (NY)N/A
PEG (5Y)0.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROCE | 5.71% | ||
| ROIC | 3.88% | ||
| ROICexc | 6.11% | ||
| ROICexgc | 14.17% | ||
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% | ||
| FCFM | 16.59% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexcg growth 3Y-34.27%
ROICexcg growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 19.4% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 4.34 | ||
| Cash Conversion | 84.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 1.68 |
F-Score5
WACC8.54%
ROIC/WACC0.45
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
EPS Next Y-9.95%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
EBIT growth 1Y-39.89%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year1.75%
EBIT Next 3Y12.4%
EBIT Next 5Y6.85%
FCF growth 1Y-7.53%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-8.67%
OCF growth 3Y14.64%
OCF growth 5Y21.85%